The Role of Public Sector Agencies in Contraceptive Research and Development

  • G. Benagiano
  • G. Perkin
  • M. Potts
Conference paper


Until recently, contraceptive product development, the translation of a research finding into a final product, was successfully carried out by profit-making, commercial pharmaceutical companies. Interaction between commercial companies, scientists, and drug-regulatory agencies has defined the steps necessary for development of a safe, acceptable, and economically feasible product. Expected financial returns from sales of the final product have driven the development process.


Contraceptive Method Family Planning Program Donor Agency Population Council Consumer Advocate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Editorial (1980) Key findings highlight diversity. People 7:5Google Scholar
  2. 2.
    Atkinson L, Schearer SB, Harkavy O (1980) Prospects for improved contraception. Fam Plann Perspect 12:173PubMedCrossRefGoogle Scholar
  3. 3.
    Wahren C (1984) The role of industry, agencies and governments in research on fertility regulation: past experience and future prospects. In: Diczfalusy A, Diczfalusy E (eds) Research on the regulation of human fertility. Scriptor, CopenhagenGoogle Scholar
  4. 4.
    UN General Assembly (1981) The least developed countries in the 1980s. UN conference on the least developed countries, A/CONF. 104/4 Add.lGoogle Scholar
  5. 5.
    UNFPA (1981) Family planning in the 1980s: challenges and opportunities. Report of the International Conference on Family Planning in the 1980s, Jakarta. New York: Population Council, New YorkGoogle Scholar
  6. 6.
    Buckles RG (1979) Contraceptive product development in public-sector programmes. PIACT paper 3Google Scholar
  7. 7.
    Population Council (1983) Stud Family Plann [Special issue] 14:159–193CrossRefGoogle Scholar
  8. 8.
    PIACT. NORPLANT® (1981) Instructions for cliniciansGoogle Scholar
  9. 9.
    Crabbe P, Archer S, Benagiano G (1983) Design of the WHO chemical synthesis programme. Steroids 41:243PubMedCrossRefGoogle Scholar
  10. 10.
    Matlin SA, Chan L, Hordjigeogiou P (1983) Analysis and purification of steroid esters. Steroids 41:359CrossRefGoogle Scholar
  11. 11.
    Enever RP, Lewis GA (1983) The influence of pharmaceutical formulation upon biological activity of esters of norethisterone. Steroids 41:359Google Scholar
  12. 12.
    Bialy G, Blye RP, Enever RP (1983) Structure activity relationships in a series of norethisterone and levonorgestrel esters. Steroids 41:419PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • G. Benagiano
    • 1
  • G. Perkin
    • 2
  • M. Potts
    • 3
  1. 1.First Institute of Obstetrics and GynecologyUniversity la SapienzaRomeItaly
  2. 2.Programme for the Introduction and Adaptation of Contraceptive TechnologySeattleUSA
  3. 3.Family Health InternationalResearch Triangle ParkUSA

Personalised recommendations